



Send a release
 Become a member Member sign in
 For journalists For bloggers
 Global sites

Search Advanced Search
 Products & Services News Releases
 →

Products & Services

Knowledge Center

Browse News Releases

Contact PR Newswire

See more news releases in [Biotechnology](#) | [Health Care & Hospitals](#) | [Medical Pharmaceuticals](#) | [Pharmaceuticals](#)

Fuisz Pharma Completes Sale of New Buccal Film Patent to MonoSol Rx



More ▾



MIAMI, Dec. 20, 2012 /PRNewswire/ -- Fuisz Pharma announced today that it has closed a transaction with MonoSol Rx whereby MonoSol Rx has acquired all rights for United States Patent #8,241,661 and its foreign counterparts. The terms of the sale were not disclosed.

Joseph Fuisz Esq., managing member for Fuisz Pharma, explained, "We are pleased to have quickly completed this transaction after a closed bidding process. We are particularly excited that the '661 patent has been acquired by MonoSol Rx. The '661 patent will complement our earlier patent filings for drug containing films, made together with other inventors for Kosmos Pharma, that were similarly acquired by MonoSol Rx and subsequently matured into a robust set of issuances."

Mr. Fuisz continued, "The MonoSol Rx patent estate has achieved a dominant position over an entire dosage form class – orally soluble films. In contrast, the patent estates in orally dissolvable tablets only protected product approaches that were ultimately substitutable in large part. As a result, we believe that MonoSol Rx is the best steward for the '661."

Richard C. Fuisz, M.D. (http://en.wikipedia.org/wiki/Richard_Carl_Fuisz), founding member for Fuisz Pharma, commented, "We are pleased to close this transaction with MonoSol Rx and look forward to announcing additional completed transactions this coming year."

Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have extensive experience working across large and specialty pharmaceutical companies. They have made substantial contributions in drug delivery including inventing and developing orally dissolving tablets and novel particle coating systems at Fuisz Technologies, inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, and independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma. Fuisz Pharma is also active in diagnostics. Fuisz Pharma has its headquarters in Miami and is not affiliated with MonoSol Rx. www.fuisz.com.

SOURCE Fuisz Pharma

RELATED LINKS
<http://www.fuisz.com>

More by this Source

Fuisz Pharma Announces Patented Film Formulations For Enhanced Buccal Drug Delivery Performance
 Oct 02, 2012, 08:00 ET

[View All News by this Source](#)

Featured Video



Wahl Makes Looking Good at the Last Minute Look Easy

Journalists and Bloggers



Visit [PR Newswire for Journalists](#) for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on [The Digital Center](#).



Next in [Biotechnology News](#)

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

[Start today.](#)

PR Newswire Membership

Fill out a [PR Newswire membership form](#) or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

[Site Preview](#)

[Close Site Preview](#)

[View FullScreen](#)